SK-216

SKU: orb1699294

Description

SK-216 is a specific PAI-1 inhibitor that suppresses tumor angiogenesis by blocking VEGF-induced HUVEC migration and tube formation in vitro. It has also demonstrated efficacy in an in vivo model, alleviating bleomycin-induced pulmonary fibrosis in mice, highlighting its research applications in oncology and fibrotic disease.

Research Area

Metabolism Research

Key Properties

• CAS Number: 654080-03-2
• MW: 533.52
• Purity: 98.29% (May vary between batches)
• Formula: C₂₉H₂₉NNa₂O₆
• SMILES: O=C([O-])C(C([O-])=O)CCCCCOC1=CC2=CC=C(C=C2C=C1)C3=NC4=CC(C(C)(C)C)=CC=C4O3.[Na+].[Na+]
• Target: PAI-1
• Solubility: H2O:5.38 mg/mL (10.08 mM)

Bioactivity

• In Vivo:
  Methods: SK-216 (6.6 μg/200 μL, intraperitoneal injection, once every three days) was used to treat a mouse model of spontaneous lung metastasis to examine whether it inhibits the lung metastasis of human osteosarcoma cells. Results: SK-216 inhibited the lung metastasis of human osteosarcoma cells from the primary lesion, but did not inhibit tumor growth.
• In Vitro:
  Methods: Human osteosarcoma cell line 143B was treated with SK-216 (0-50 μM, hours), and the expression of target proteins was detected by Western blot. Results: SK-216 at concentrations of 25 and 50 μM inhibited PAI-1 expression by 40%, resulting in a significant decrease in the ratio of cell invasion pores to total pores, and was able to inhibit the secretion of MMP-13 in 143B cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SK216, SK-216, SK216.Plasminogen activator inhibitor-1 (PAI-1) inhibitor, SK 216

Compound Identifiers

PubChem CID

131882845